Cargando…

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses

Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer targets—EG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menotti, Laura, Avitabile, Elisa, Gatta, Valentina, Malatesta, Paolo, Petrovic, Biljana, Campadelli-Fiume, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070899/ https://www.ncbi.nlm.nih.gov/pubmed/29966356 http://dx.doi.org/10.3390/v10070352

Ejemplares similares

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
por: Leoni, Valerio, et al.
Publicado: (2017)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
por: Gatta, Valentina, et al.
Publicado: (2015)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
por: De Lucia, Maria, et al.
Publicado: (2020)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Human herpesvirus 6: An emerging pathogen.
por: Campadelli-Fiume, G, et al.
Publicado: (1999)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
por: Hill, Claudia, et al.
Publicado: (2021)

Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus
por: Lal, Sangeet, et al.
Publicado: (2017)

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
por: Niemann, Julia, et al.
Publicado: (2019)

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus
por: Suzuki, Takuma, et al.
Publicado: (2021)

αvβ6- and αvβ8-Integrins Serve As Interchangeable Receptors for HSV gH/gL to Promote Endocytosis and Activation of Membrane Fusion
por: Gianni, Tatiana, et al.
Publicado: (2013)

Spotlight on… Gabriella Campadelli-Fiume
por: Campadelli-Fiume, Gabriella
Publicado: (2018)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

CD47-retargeted oncolytic adenovirus armed with melanoma differentiation-associated gene-7/interleukin-24 suppresses in vivo leukemia cell growth
por: Li, Gongchu, et al.
Publicado: (2015)

αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
por: Vannini, Andrea, et al.
Publicado: (2019)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
por: Ayala Breton, Camilo, et al.
Publicado: (2015)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4(+) GBM cells: A proof of principle
por: Sanchez Gil, Judit, et al.
Publicado: (2022)

Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host’s Innate Antiviral Immunity to Attack Tumor Cells
por: Fu, Xinping, et al.
Publicado: (2020)

The Epithelial αvβ3-Integrin Boosts the MYD88-Dependent TLR2 Signaling in Response to Viral and Bacterial Components
por: Gianni, Tatiana, et al.
Publicado: (2014)

In Vivo Safety, Biodistribution and Antitumor Effects of uPAR Retargeted Oncolytic Measles Virus in Syngeneic Cancer Models
por: Jing, Yuqi, et al.
Publicado: (2014)

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia
por: Betancourt, Dillon, et al.
Publicado: (2015)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
por: Hall, Bonnie L., et al.
Publicado: (2020)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eikl9ak8s5vnbrci5jvrlkjktl